Loading interface...

Resochin 64.5 MG Injection

Manufactured byBayer Pharmaceuticals Pvt. Ltd.
ContainsChloroquine
Description

Resochin 64.5 MG Injection is an antimalarial medication used for the treatment of severe malaria caused by Plasmodium falciparum and Plasmodium vivax strains in patients who have not adequately responded to other antimalarial medications or unable to receive oral therapy.

Side effects

Major & minor side effects for Resochin 64.5 MG Injection

  • Blurred vision
  • Confusion
  • Dizziness
  • Skin rash
  • Hair loss
  • Increased sensitivity of the skin to sunlight
  • Injection site pain
  • Double vision
  • Diarrhea

Uses of Resochin 64.5 MG Injection

What is it prescribed for?

  • Malaria
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The amount of time required for this medicine to show its action is not clinically established.
  • How long do the effects of this medicine last?
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Is it safe to consume alcohol while taking this medicine?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is this a habit forming medicine?
    No habit forming tendencies were reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.

Allergy

This medicine is not recommended for use in patients with a known allergy to chloroquine, 4-aminoquinolones, or any other inactive ingredients present in the formulation.

Retinal or visual field changes

This medicine is not recommended for use in patients with any vision impairment due to the risk of worsening of the patient's condition.

Psoriasis

This medicine is not recommended for use in patients with active psoriasis (a skin disorder characterized by dry and scaly patches) as it may worsen the patient's condition.

Porphyria

This medicine is not recommended for use in patients with porphyria (a condition where there is an excess buildup of porphyrin in the body) as it may worsen the patient's condition.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.
General warnings

QT interval prolongation

This medicine should be used with extreme caution in patients suffering from QT prolongation due to the increased risk of worsening of the patient's condition. Close monitoring of heart function and vital signs, appropriate dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Eye disorders

This medicine may increase the risk of vision problems. This effect depends on the dose and duration of the treatment. Close monitoring of eye function is necessary. Any symptoms of a vision problem should be reported to the doctor.

Blood cell count

This medicine may lower the blood cell count if taken for a longer time. Close monitoring of complete blood cell count is necessary. Discontinue the treatment if any signs of low blood cell count appear. It should be used with caution in patients with glucose-6 phosphate dehydrogenase deficiency.

Hearing problem

This medicine may increase the risk of hearing problems and hence should be used with extreme caution in patients with existing auditory defects or problems. Close monitoring of the clinical condition, appropriate dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

Impaired liver function

This medicine should be used with caution in patients with liver diseases due to the increased risk of severe adverse effects. Close monitoring of liver function is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.

Hypoglycemia

This medicine may lower the blood sugar levels drastically in some patients. Close monitoring of the blood sugar levels, appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

Other uses

Your doctor may prescribe this medicine for indications other than those stated above in certain specific circumstances, especially if other medicines are not effective. All the risks and benefits should be discussed with the doctor in such cases.

Missed Dose

Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of a missed dose is very low.

Overdose

Since this medicine is administered in the hospital setting by a qualified healthcare professional, the likelihood of an overdose is very less. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Ethambutol

Fluconazole

Tramadol

Quinidine

Chlorpromazine

Disease interactions

Oculotoxicity

This medicine is not recommended in patients with retinal or visual field changes. The treatment should be discontinued if any symptoms of blurred vision, light flashes, and streaks, difficulty in reading, etc. An alternative treatment option should be considered based on the clinical condition.

Seizures

This medicine should be used with caution in patients with seizures due to the increased risk of severe adverse effects. Close monitoring of the clinical condition, appropriate dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

Liver impairment

This medicine should be used with caution in patients with liver diseases due to the increased risk of severe adverse effects. Close monitoring of liver function is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.
Food interactions
Information not available.
Lab interactions
Information not available.
This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine.
Miscelleneous

Usage does not depend on food timings

To be taken as instructed by doctor

May cause sleepiness

How it works
This medicine works by increasing the concentration of a toxic molecule in the parasite thus inhibits the growth of the parasite.
Legal Status

Approved

Approved

Unknown

Unknown

Classification

Category

Antimalarial Quinolines

Schedule

Schedule H

Chloroquine - DrugBank [Internet]. Drugbank.ca. 2019 [cited 3 October 2019]. Available from:

https://www.drugbank.ca/drugs/DB00608

Chloroquine [Internet]. Pubchem.ncbi.nlm.nih.gov. 2019 [cited 3 October 2019]. Available from:

https://pubchem.ncbi.nlm.nih.gov/compound/chloroquine

[Internet]. Accessdata.fda.gov. 2019 [cited 30 September 2019]. Available from:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/06002slr039_aralen_lbl.pdf
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 3 Oct 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.